MCK Q4 2026

Q1 2027 Q4 2026 Q3 2026 Q2 2026 Q1 2026

Earnings

McKesson delivered a mixed fiscal fourth-quarter report for Q4 2026, posting adjusted EPS of $11.69 that edged past the $11.57 consensus estimate by 1.05%, while revenue of $96.30 billion fell short of the $101.38 billion Wall Street expected, a 5.02… Read more McKesson delivered a mixed fiscal fourth-quarter report for Q4 2026, posting adjusted EPS of $11.69 that edged past the $11.57 consensus estimate by 1.05%, while revenue of $96.30 billion fell short of the $101.38 billion Wall Street expected, a 5.02% miss, despite growing 6.0% year over year. The headline earnings strength was anchored by the Oncology and Multispecialty segment, where revenue surged 35% to $12.71 billion and adjusted operating profit climbed 53% to $385.00 million, fueled by specialty distribution growth and contributions from recent acquisitions including PRISM Vision and Core Ventures. North American Pharmaceutical, which accounts for the bulk of McKesson's revenue at $79.12 billion in the quarter, also contributed with 11% adjusted operating profit growth. The results come as pharmaceutical distribution peers broadly navigate pricing headwinds across the industry. Looking ahead, McKesson guided fiscal 2027 adjusted EPS to a range of $43.80 to $44.60, representing 12% to 14% growth, while reaffirming long-term annual EPS expansion targets of 13% to 16%.